Dr. Joseph George Kamel, DO

Dr. Kamel practices at P. James Voloshin M.D., Inc in Newport Beach, California.

Dr. Kamel's NPI, 1003304759, was assigned on April 27, 2018. Dr. Kamel graduated from WesternU College of Osteopathic Medicine of the Pacific in 2018. Dr. Kamel holds California license 20A19263.

Dr. Kamel's primary practice is P. James Voloshin M.D., Inc, at 360 San Miguel Dr, Newport Beach, CA 92660 in Orange County. The practice phone is (949) 759-0995.

Dr. Kamel's primary practice is P. James Voloshin M.D., Inc in Newport Beach, California. Dr. Kamel is also affiliated with UCI Health - Orange. The medical group on file is Island Dermatology. Dmand AI also links Dr. Kamel to 1 more physician office, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kamel practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Kamel's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Kamel is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Kamel's licenses on file in 2 states: California and Michigan.

Dmand AI lists acne, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, corns and calluses, hives and itchy rashes among the conditions Dr. Kamel treats.

CMS data shows 3,251 Medicare services from Dr. Kamel across 17 procedure codes in 2024, for 569 Medicare patients. Medicare paid $230,406 for them. Every service was in an office.

CMS counts 569 Medicare patients who saw Dr. Kamel in 2024. The largest group is 65 to 74, with 278 patients. 75% of them have high cholesterol, and 65% have high blood pressure. 10% are also on Medicaid. Their average risk score is 1.04, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Kamel's median patient age at 67, with 44% women.

In 2024, Dr. Kamel wrote 738 Medicare Part D claims for 297 patients. 94% of them were for generic drugs. CMS names the drug for 629 of them, across 18 drugs with 11 or more claims each, at $61,828 in total drug cost. In 2023, CMS named 616 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Kamel for performance year 2024, reported as part of a group. Dr. Kamel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 448 procedures of skin biopsy by Dr. Kamel, more than 95% of the clinicians it reports for that procedure.

Removal of nail tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 4 papers to Dr. Kamel, published from 2015 to 2017. Dr. Kamel's most frequent co-authors are Kyle T. Amber, MD, Estefania Larrosa, MD and Jenifer R. Lloyd, DO.

Dmand AI links Dr. Kamel to 1 clinical trial. Conditions studied include Psoriasis and Skin Diseases, Papulosquamous.

CMS Open Payments shows 240 general payments to Dr. Kamel from 24 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 51% of the total. UCB, Inc. paid the most, $3,720.

Dr. Kamel graduated from WesternU College of Osteopathic Medicine of the Pacific in 2018. Dr. Kamel is a member of AAD.

Dr. Kamel is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Humana. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.